Cargando…

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System

BACKGROUND: Vaccination against coronavirus disease 2019 (COVID-19) is underway globally to prevent the infection caused by the severe acute respiratory syndrome coronavirus 2. We aimed to investigate the adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Minji, Kim, Jehun, Oh, Chi Eun, Lee, Jin-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093606/
https://www.ncbi.nlm.nih.gov/pubmed/33942578
http://dx.doi.org/10.3346/jkms.2021.36.e114
_version_ 1783687846591201280
author Jeon, Minji
Kim, Jehun
Oh, Chi Eun
Lee, Jin-Young
author_facet Jeon, Minji
Kim, Jehun
Oh, Chi Eun
Lee, Jin-Young
author_sort Jeon, Minji
collection PubMed
description BACKGROUND: Vaccination against coronavirus disease 2019 (COVID-19) is underway globally to prevent the infection caused by the severe acute respiratory syndrome coronavirus 2. We aimed to investigate the adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs). METHODS: This was a retrospective study of the AEFIs associated with the first dose of the ChAdOx1 nCoV-19 vaccine at the Kosin University Gospel Hospital from March 3 to March 22, 2021. We investigated the systemic and local adverse events during the 7 days following the vaccination using the Mobile Vaccine Adverse Events Reporting System (MVAERS) developed by our hospital. RESULTS: A total of 1,503 HCWs were vaccinated, and the data of 994 HCWs were reported in the MVAERS. The most commonly reported AEFIs were tenderness at the injection site (94.5%), fatigue (92.9%), pain at the injection site (88.0%), and malaise (83.8%). The severity of most AEFIs was mild-to-moderate, and the severity and number of AEFIs were less in the older age group. There were no serious events requiring hospitalization, and most AEFIs improved within a few days. CONCLUSION: The AEFIs associated with the ChAdOx1 nCoV-19 vaccine were tolerable, and the use of the MVAERS was helpful in monitoring the AEFIs. The use of MVAERS will help in sharing accurate and ample information about vaccination against COVID-19.
format Online
Article
Text
id pubmed-8093606
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-80936062021-05-12 Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System Jeon, Minji Kim, Jehun Oh, Chi Eun Lee, Jin-Young J Korean Med Sci Original Article BACKGROUND: Vaccination against coronavirus disease 2019 (COVID-19) is underway globally to prevent the infection caused by the severe acute respiratory syndrome coronavirus 2. We aimed to investigate the adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs). METHODS: This was a retrospective study of the AEFIs associated with the first dose of the ChAdOx1 nCoV-19 vaccine at the Kosin University Gospel Hospital from March 3 to March 22, 2021. We investigated the systemic and local adverse events during the 7 days following the vaccination using the Mobile Vaccine Adverse Events Reporting System (MVAERS) developed by our hospital. RESULTS: A total of 1,503 HCWs were vaccinated, and the data of 994 HCWs were reported in the MVAERS. The most commonly reported AEFIs were tenderness at the injection site (94.5%), fatigue (92.9%), pain at the injection site (88.0%), and malaise (83.8%). The severity of most AEFIs was mild-to-moderate, and the severity and number of AEFIs were less in the older age group. There were no serious events requiring hospitalization, and most AEFIs improved within a few days. CONCLUSION: The AEFIs associated with the ChAdOx1 nCoV-19 vaccine were tolerable, and the use of the MVAERS was helpful in monitoring the AEFIs. The use of MVAERS will help in sharing accurate and ample information about vaccination against COVID-19. The Korean Academy of Medical Sciences 2021-04-13 /pmc/articles/PMC8093606/ /pubmed/33942578 http://dx.doi.org/10.3346/jkms.2021.36.e114 Text en © 2021 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jeon, Minji
Kim, Jehun
Oh, Chi Eun
Lee, Jin-Young
Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
title Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
title_full Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
title_fullStr Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
title_full_unstemmed Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
title_short Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
title_sort adverse events following immunization associated with coronavirus disease 2019 vaccination reported in the mobile vaccine adverse events reporting system
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093606/
https://www.ncbi.nlm.nih.gov/pubmed/33942578
http://dx.doi.org/10.3346/jkms.2021.36.e114
work_keys_str_mv AT jeonminji adverseeventsfollowingimmunizationassociatedwithcoronavirusdisease2019vaccinationreportedinthemobilevaccineadverseeventsreportingsystem
AT kimjehun adverseeventsfollowingimmunizationassociatedwithcoronavirusdisease2019vaccinationreportedinthemobilevaccineadverseeventsreportingsystem
AT ohchieun adverseeventsfollowingimmunizationassociatedwithcoronavirusdisease2019vaccinationreportedinthemobilevaccineadverseeventsreportingsystem
AT leejinyoung adverseeventsfollowingimmunizationassociatedwithcoronavirusdisease2019vaccinationreportedinthemobilevaccineadverseeventsreportingsystem